Cinnarizine was synthesized and patented by Janssen Pharmaceutica in 1958. It is a piperazine with the structure (E)-1-(diphenylmethyl)-4-(3 phenyl-2-propenyl) piperazine.
The drug cinnarizine has been shown to have several important therapeutic activities but the pharmacological link between them is not always clear. It was originally used as an antihistamine (Zolov 1961) . A natural development was its use in the prevention of motion sickness (Trumbull et al. 1960 , Cobb et al. 1976 ). However, it first became widely used in the United Kingdom as a specific anti-vertigo agent (Philipszoon 1962 , Dix & Morales-Garcia 1972 . More recently its action as an inhibitor of vaso-constriction (Van Nueten 1969) has created great interest. It now seems clear that cinnarizine treatment improves peripheral blood flow in patients with peripheral vascular disease. The mechanism is not yet fully understood but may involve a direct effect on the blood itself (Di Perri et al. 1977 ). In addition, recent research has shown cinnarizine to be an anti-asthmatic agent (Emanuel et al. 1978) .
The relative importance of these therapeutic activities is difficult to assess. The anti-vertigo activity and the effect in improving peripheral blood flow are the most widely documented and researched. Many studies have shown the efficacy of cinnarizine in these indicatioa but again, the mechanism of action is still open to some speculation. In both cases an improvement in blood flow may be the reason for clinical improvement. This report will initially examine certain clinical findings in peripheral vascular disease and then attempt to relate these clinical data to the pharmacological properties of the drug. The Treatment ofPeripheral Vascular Disease As early as 1968 a number of reports appeared in uncontrolled studies, claiming a specific effect of cinnarizine in the treatment of intermittent claudication secondary to atherosclerosis. Pfeffer (1968) published a trial involving 161 patients. After 4-6 weeks of therapy he claimed worthwhile improvement in 102. Improvement was seen both clinically and objectively by means ofoscillography and exercise tolerance using a foot pedal. Similarly, Verdonk (1968) reported symptomatic and objective improvement in 90 % of 50 atherosclerotic patients after 8 weeks of therapy with cinnarizine. From these and other early reports (Joos 1968 , Put 1969 it was clear that the drug was exceptionally well tolerated and so a series of controlled double-blind studies was set up in an attempt to verify these results.
The first ofthesecontrolledstudies (Andriaensen 1969) compared the chronic effects of cinnarizine with placebo on blood flow in the lower limbs of 18 claudicants. This randomized, double-blind, non-cross-over study over an 8 week period assessed the severity of peripheral vascular disease before and after treatment, both clinically and by measurement of blood flow through the legs using the Lassen 18sxenon clearance technique. The results were reported as changes per leg. In the cinnarizine group, a marked clinical improvement was seen in 44 % of legs and this was associated with an increased maximum rate of blood flow through the ischtmic leg muscle. In the placebo group marked improvement was seen in no legs and deterioration in 22 %. Schuermans et al. (1971) confirmed these findings in a double-blind study on 23 arteriosclerotic patients treated with cinnarizine (75 mg three times daily) or placebo for 3 months. Results were assessed as changes in peripheral blood flow using the isotope build-up technique; finger plethysmography after ischemia induced by arterial occlusion and functional muscle capacity using Miglietta's isotonometric technique. Three months of cinnarizine treatment significantly enhanced muscle capacity (P<0.05) and increased the post-ischemic blood flow (P<0.005), compared to placebo, when the data were analysed by the Mann-Whitney U-test. No change in heart rate or blood pressure was seen and no side effects were observed. Verhaegen and co-workers (1974) subsequently reported data on 43 patients suffering from generalized arteriosclerosis. A variety of noninvasive studies were carried out to determine if cinnarizine was of value in the treatment of peripheral vascular occlusive disease and to establish which non-invasive methods were of greatest value for evaluating vascular status.
The authors reached the following conclusions:
(1) Cinnarizine is long acting and effective by the oral route.
(2) It is devoid of any side effect on sympathetic reflexes, resting blood pressure or pulse rate. It is well tolerated by patients being concurrently treated with antihypertensive agents and cardiac glycosides.
(3) It improves post-ischTmic blood flow.
(4) There is no steal effect. In patients with intermittent claudication, improvement was more marked in the lower than in the upper extremity. An increased post-exercise arm-ankle pressure gradient indicated that more blood was shunted to the exercising muscle. In this respect cinnarizine contrasts with vasodilator drugs which may prove harmful by diverting blood away from the affected muscles.
(5) Differentiated pulse plethysmography reliably estimated vascular distention. Venous occlusion plethysmography appeared to be an accurate, reliable, sensitive and reproducible quantitative method for measuring blood flow in an extremity.
Verhaegen's findings created an increased interest in the assessment of the action of cinnarizine using mercury strain gauge plethysmography. Forconi et al. (1976) studied peripheral blood flow in normal subjects and patients suffering from peripheral obliterative arterial disease using this technique. They found that rest flow was significantly increased in both the muscle and skin of normal subjects and in the most affected limb of sclerotic patients after a single dose of 300 mg of cinnarizine. Post-ischiemic reactive hypertmia remained unchanged in the patients and decreased in the normal subjects following drug treatment. In the pre-treatment control study, the latter had a more than doubled post-ischmmic hypernmic response. Ellis et al. (1975) studied the vascular effects of 7 days of cinnarizine therapy on post-exercise flow in claudicants using mercury strain gauge plethysmography. They found significant median flow increases compared to rest values at 1 and 3 min after exercise. This increase in ischmemic flow after chronic treatment contrasts with the single dose acute finding of Forconi et al. (1976) .
These investigations all used sophisticated techniques and equipment in order to provide objective evidence of changes in blood flow. However, Staessen (1977a Staessen ( , 1977b has recently studied cinnarizine in a situation more closely related to the general management of typical patients with peripheral vascular disease. In a multi-centre, double-blind, placebo-controlled study he compared the effects of 4 months of cinnarizine treatment (28 patients) to placebo (29 patients). The placebo in this study contained 15 mg of phenobarbitone given twice daily to reproduce any mild sedative effect of cinnarizine compared to placebo.
Cinnarizine patients reported significant amelioration of symptoms described as intermittent claudication, muscular cramps, cold extremities and vascular spasm. Seventy-eight percent of cinnarizine patients showed improvement classified as good to excellent compared to 14% of placebo patients. Walking distance was assessed at the beginning and end of treatment by all claudicants. There was a marked placebo response with 30 % of placebo patients reporting at least a doubling of walking distance. However, 75 % of patients treated with cinnarizine reported an increased walking distance of at least twice the original value, and the difference in favour of cinnarizine was statistically significant (P<0.05).
Staessen considered cinnarizine to be significantly more effective than placebo in the treatment of peripheral vascular disease, and reported almost no side effects. Patients on cinnarizine showed one case of a tingling sensation in the skin with itching; one case of gastric intolerance and one of drowsiness and fatigue. In contrast, 12 patients on placebo reported the same and other side effects. Table 1 summarizes the most important clinical and pharmacological studies relating to cinnarizine and its use in peripheral vascular disease. From these various reports it seems clear that cinnarizine has marked activity in the treatment of this condition, and the remainder of this review will attempt to analyse the possible pharmacological mechanisms by which this clinical action may be brought about.
Pharmacokinetics and Dosage
The absorption, distribution and metabolism of cinnarizine have been extensively studied. Elimination is both fiecal and urinary. Metabolism and excretion have been investigated in rats (Allewijn 1968 , Soudijn & van Wijngaarden 1968 , Janssen Pharmaceutica 1972a and in man (Janssen Pharmaceutica 1972b). Allewijn (1968) reported that after oral administration to rats, rapid absorption occurred from the gastrointestinal tract and peak tissue radioactivity levels were reached within 1 h in most tissues. Extensive metabolism occurred within 30 min of treatment and after 32 h the tissue levels were negligible.
Soudijn & Van Wijngaarden (1968) using 14C parenteral cinnarizine confirmed that it is extensively metabolized, N-dealkylation and ring hydroxylation being the major pathways. About one-third of the radioactive metabolites were excreted in the urine and two-thirds in the faeces.
In a further rat study (Janssen Pharmaceutica 1972a), 81 % of the administered oral dose of radioactive labelled 14C cinnarizine was excreted within 4 days. Of this, 64 % was excreted on day 1, 13 % in urine and 51 % in faeces. About 25% of the administered dose was excreted in feces as unchanged cinnarizine. Thus absorption was approximately 75 %. Only I % of unchanged cinnarizine was found in the urine so that metabolism by that pathway was virtually complete. Peak plasma levels are obtained 4-8 h after oral administration of a single 75 mg dose (Janssen Pharmaceutica (1972b) .
The Mode ofAction ofCinnarizine
Of the considerable number of pharmacological studies which have been performed on cinnarizine, those related to the mode of action of the drug in the treatment of peripheral vascular disease include:
(1) Inhibition of calcium flux across muscle cell membranes.
(2) Inhibition of contraction of arterial smooth muscle cells.
(3) Effects leading to enhanced muscle capacity.
(4) Direct effects on blood viscosity. (5) Effects on proliferation of the arterial wall.
Effects on Calcium Ion Transport
Although at present the exact mode of action of the drug is uncertain, its anti-vasoconstrictor activity may be due to the inhibition of calcium ion entry into the smooth muscle cells. However, this simple picture has been recently complicated by the discovery of direct effects on the erythrocyte (Di Perri et al. 1977 ). These may be related to calcium entry into the red cell and it is this blockade of calcium transport which may be central to a seeming multiplicity of action. Godfraind & Kaba (1972) have discussed fully the role of calcium in the action of drugs on vascular smooth muscle. They conclude that the contraction of arterial smooth muscle in response to spasmogens is dependent upon the presence of calcium. Previously it had been shown that noradrenaline acted both by increasing the membrane permeability to calcium and also by releasing the calcium sequestered in the muscle cell (Godfraind & Kaba 1969) . The dissociation of these two actions was established in the rat aorta which shows both a phasic and a tonic contraction in response to catecholamines. It was observed that the tonic contraction was dependent on the calcium concentration of the medium, whereas the phasic contraction was only depressed after almost total removal of calcium ions. Cinnarizine was shown by these authors to block only the tonic contraction induced by noradrenaline in the rat aorta. It also inhibited the calcium redistribution evoked by either noradrenaline or potassium depolarization. It therefore appears that inhibition of the tonic contraction may be related to the inhibition of the calcium transfer from outside to inside the cell occurring when the smooth muscle is stimulated by a spasmogenic agent.
A subsequent report by Godfraind et al. (1973) demonstrated an increase of radioactive-labelled calcium in muscle tissue after depolarization or stimulation by noradrenaline. This increase was prevented by cinnarizine. More recently, Godfraind & Morel (1977) have reported experiments using tritium labelling and demonstrated that cinnarizine may act by inhibiting the opening of calcium channels associated with-smooth muscle excitation. These authors have shown a saturable cinnarizine uptake within that range of cinnarizine concentration which inhibited the contraction evoked by potassium depolarization.
The calcium blocking effect also has important implications, not only for muscle cells but also in relation to red cell deformability. Weed et al. (1969) have suggested that changes in the physical properties of the red cell occur as a consequence of reversible sol-gel transformation mediated by calcium and ATP and taking place at the interface between the cell membrane and the soluble interior of the cell. This effect is discussed more fully in the later section on cinnarizine and blood viscosity.
Anti-vasoconstrictive Efjects on

Arterial Smooth Muscle
The concept of anti-vasoconstriction has historically been the subject of some confusion, and it is important to distinguish anti-vasoconstriction from vasodilation. A well-established clinical analogy exists in respiratory medicine, where there is a clear and well understood difference between bronchodilators and drugs such as cromoglycate which act protectively to prevent bronchoconstriction. Similarly, nicotinic acid derivatives act as peripheral vasodilators. Pharmacologically, cinnarizine acts protectively to inhibit vasoconstriction. Van Nueten (1968) described the action of cinnarizine on the vasoconstrictor effects of vasoactive agents in perfused peripheral arteries from the rabbit ear (Table 2) .
In a further comparative study (Van Nueten 1969) It was concluded that cinnarizine was the most potent and long-acting of the drugs tested in this experimental system (Fig 1) . Van Nueten & Janssen (1972) also studied the effectiveness of cinnarizine as an inhibitor of noradrenaline-induced vasoconstriction in the perfused hind leg of the anesthetized dog. They found that the peripheral resistance of the vascular bed was reduced without changing systemic arterial blood pressure or heart rate. These experiments reinforced earlier reports by Lecomte et al. (1965) and Godfraind & Kaba (1969) which also demonstrated a reduction by cinnarizine of the response to noradrenalineinduced vasoconstriction.
Finally, it has been shown that cinnarizine is devoid of any specific anticholinergic effects and Effects Leading to Enhanced Muscle Capacity Schuermans et al. (1971) demonstrated that cinnarizine significantly enhanced functional muscle capacity in patients with peripheral arterial disease. Miglietta (1969) reported that during nerve stimulation under ischemic conditions the muscle action potential remains unchanged whilst the contraction fails. He inferred that the muscle fatigue observed in the isotonometric test was caused by failure of the excitation contraction coupling mechanism or by exhaustion of the energy store. During exercise, venous oxygen saturation decreases and lactic acid concentration increases more rapidly in chronically hypoxic than in healthy muscle. Increased muscle force may be a result of more effective blood flow. The effect of cinnarizine in improving muscle performance may be an indication of the action of the drug on the muscle energy store reserves, through a change in muscle metabolism from more anaerobic to more aerobic. A direct action is also possible, since cinnarizine is a specific blocker of calcium entry into depolarized smooth muscle and since an increase in intracellular calcium leads to muscle contraction and the utilization of energy stores in the form of ATP (Davies 1965). It is possible, therefore, that cinnarizine therapy may cause a direct relaxation of muscle tone and a more efficient usage of the energy store of the muscle fibre. Direct Effects on Blood Viscosity Dormandy, Hoare, Cobley, Arrowsmith & Dormandy (1973) have demonstrated that increased blood viscosity is an important factor in reducing blood flow in patients with intermittent claudication, and in some patients increased viscosity seemed to be the determining cause of the condition. Subsequent studies have shown an elevation in blood viscosity in patients with Raynaud's phenomenon (Goyle & Dormandy 1976) and diabetic microcirculatory disease (Barnes et al. 1977) . Dormandy, Hoare, Khattab & Arrowsmith (1973) also showed that there existed a significant correlation between progressive deterioration of the peripheral circulatory disturbance and the initial blood viscosity.
It is clear that blood viscosity is determined by a combination of biochemical and biophysical factors, divisible into plasma factors and red cell factors. Plasma fibrinogen is thought to be the most important plasma factor (Merrill 1969) . However, Rosenblum (1969) has shown that plasma fibrinogen affects blood viscosity by increasing red cell aggregation and so plasma and red cell factors cannot be considered indepen-dently. Weed et al. (1969) studied red cell deformability, after noting in a previous study (Weed & Bowdler 1966 ) that ATP-depleted blood manifested a gross increase in viscosity, associated with an increase in erythrocyte rigidity. They concluded that red cell deformability is dependent on a reversible reaction mediated by ATP and calcium at the level of the red cell membrane. It is postulated that calcium ions react with soluble intracellular protein to make the latter insoluble and hence become associated with the membrane.
Di Perri et at. (1977) described the action of cinnarizine on the hyperviscosity of blood in patients with peripheral obliterative arterial disease. Cinnarizine administration decreased the whole blood viscosity in these patients, without affecting the plasma or serum viscosity, himatocrit, plasma fibrinogen concentration or plasma osmolality. It is suggested that the improvement induced by cinnarizine in blood flow in patients with peripheral vascular disease may be due to an increased deformability of the red cells.
Effects on Proliferation ofthe
Arterial Wall Connective Tissue Ross & Glomset (1976) have suggested that the primary event in atherogenesis is division of transformed smooth muscle and that plaque is a benign tumour invading the lumen from the media. Elkeles (1969) reported that calcium can be found in the media of human aortas and coronary arteries after the age of 20 years and that it increases steadily with age. He recently also confirmed the relationship between atherosclerosis, arterial calcium and alpha radiation produced by heavy metals that accumulate in the media together with calcium (Elkeles 1977) .
It is of interest, therefore, that Schmitt et al. (1974) have reported an increased proliferation of connective tissue in the walls of rat veins and arteries after injection of somatotropin or after blood pressure increase induced by stenosis of the vessel. The proliferation induced by pressure in the aortic wall was decreased by administration of cinnarizine. The significance of this finding in human peripheral vascular disease is unclear.
